- Home
- NMI vs PROK Comparison
NMI vs PROK Comparison
Compare NMI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMI
- PROK
- Stock Information
- Founded
- NMI 1988
- PROK 2015
- Country
- NMI United States
- PROK United States
- Employees
- NMI N/A
- PROK N/A
- Industry
- NMI Trusts Except Educational Religious and Charitable
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMI Finance
- PROK Health Care
- Exchange
- NMI Nasdaq
- PROK Nasdaq
- Market Cap
- NMI 97.0M
- PROK 85.5M
- IPO Year
- NMI N/A
- PROK N/A
- Fundamental
- Price
- NMI $9.88
- PROK $3.29
- Analyst Decision
- NMI
- PROK Buy
- Analyst Count
- NMI 0
- PROK 5
- Target Price
- NMI N/A
- PROK $6.25
- AVG Volume (30 Days)
- NMI 28.4K
- PROK 37.8M
- Earning Date
- NMI 01-01-0001
- PROK 08-08-2025
- Dividend Yield
- NMI 4.10%
- PROK N/A
- EPS Growth
- NMI N/A
- PROK N/A
- EPS
- NMI N/A
- PROK N/A
- Revenue
- NMI N/A
- PROK $306,000.00
- Revenue This Year
- NMI N/A
- PROK $85.21
- Revenue Next Year
- NMI N/A
- PROK N/A
- P/E Ratio
- NMI N/A
- PROK N/A
- Revenue Growth
- NMI N/A
- PROK N/A
- 52 Week Low
- NMI $8.30
- PROK $0.46
- 52 Week High
- NMI $10.05
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- NMI 46.49
- PROK 60.03
- Support Level
- NMI $9.81
- PROK $2.80
- Resistance Level
- NMI $10.02
- PROK $4.05
- Average True Range (ATR)
- NMI 0.21
- PROK 1.11
- MACD
- NMI -0.03
- PROK -0.07
- Stochastic Oscillator
- NMI 7.62
- PROK 37.15
About NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.